Literature DB >> 2076464

Structural characterization by mass spectrometry of native and recombinant human relaxin.

J T Stults1, J H Bourell, E Canova-Davis, V T Ling, G R Laramee, J W Winslow, P R Griffin, E Rinderknecht, R L Vandlen.   

Abstract

Mass spectrometry has played a key role in characterizing the primary structure of native and recombinant relaxin, a peptide hormone that induces ripening of the cervix prior to childbirth. The peptide is composed of two chains, A and B, and is formed from a single-chain prohormone, as is insulin. Aside from conserved cysteines, though, it has little sequence homology with insulin. Due to the small amounts of native peptide initially available (less than 10 pmol), traditional techniques could not provide information on the blocked A-chain sequence, on the carboxyterminal sequences, nor on other possible post-translational modifications. Mass measurements by fast atom bombardment (FAB) were made on reduced human relaxin isolated from corpora lutea. The detection limit by FAB for reduced relaxin was 500 fmol. The B-chain was four amino acids shorter than expected from comparison of the previously known cDNA sequence with homologous rat and porcine sequences. The A-chain, as predicted, was 24 amino acids in length and had a pyroglutamic acid residue on the amino-terminus. The purified samples were homogeneous with no other post-translational modifications. The recombinant relaxin molecule was also extensively characterized by mass spectrometry. In addition to the intact molecule, all tryptic peptides were characterized by FAB. A capillary high-performance liquid chromatography continuous-flow FAB system, developed for high-sensitivity peptide mapping, aided in these analyses. Finally, the three disulfide bonds were shown by tandem mass spectrometry to match those of insulin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076464     DOI: 10.1002/bms.1200191105

Source DB:  PubMed          Journal:  Biomed Environ Mass Spectrom        ISSN: 0887-6134


  7 in total

1.  Reversed-phase liquid chromatography in-line with negative ionization electrospray mass spectrometry for the characterization of the disulfide-linkages of an immunoglobulin gamma antibody.

Authors:  Dirk Chelius; Mary E Huff Wimer; Pavel V Bondarenko
Journal:  J Am Soc Mass Spectrom       Date:  2006-08-14       Impact factor: 3.109

Review 2.  Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease.

Authors:  Yifang Li; Sharon D Ricardo; Chrishan S Samuel
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

Review 3.  Assessment and significance of protein-protein interactions during development of protein biopharmaceuticals.

Authors:  Sandeep Yadav; Jun Liu; Thomas M Scherer; Yatin Gokarn; Barthélemy Demeule; Sonoko Kanai; James D Andya; Steven J Shire
Journal:  Biophys Rev       Date:  2013-03-14

4.  The kinetics of relaxin oxidation by hydrogen peroxide.

Authors:  T H Nguyen; J Burnier; W Meng
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

5.  Primate relaxin: synthesis of gorilla and rhesus monkey relaxins.

Authors:  J D Wade; S S Layden; P F Lambert; H Kakouris; G W Tregear
Journal:  J Protein Chem       Date:  1994-04

6.  Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design.

Authors:  Annunziata D'Ercole; Silvia Nistri; Lorenzo Pacini; Alfonso Carotenuto; Federica Santoro; Anna Maria Papini; Ross A D Bathgate; Daniele Bani; Paolo Rovero
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

7.  Male Seminal Relaxin Contributes to Induction of the Post-mating Cytokine Response in the Female Mouse Uterus.

Authors:  Danielle J Glynn; Kee Heng; Darryl L Russell; David J Sharkey; Sarah A Robertson; Ravinder Anand-Ivell; Richard Ivell
Journal:  Front Physiol       Date:  2017-06-19       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.